Silk Road Medical Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Silk Road Medical stock.
View analyst ratings for Silk Road Medical or view top-rated stocks.

Wall Street analysts have given Silk Road Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Silk Road Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Silk Road Medical saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 2,180,000 shares, a decrease of 22.7% from the February 28th total of 2,820,000 shares. Based on an average daily volume of 390,100 shares, the short-interest ratio is currently 5.6 days.
View Silk Road Medical's Short Interest.

Silk Road Medical is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Silk Road Medical.

Silk Road Medical, Inc (NASDAQ:SILK) posted its quarterly earnings data on Monday, March, 1st. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.21. The company earned $21.10 million during the quarter, compared to analysts' expectations of $21.35 million. Silk Road Medical had a negative trailing twelve-month return on equity of 40.79% and a negative net margin of 53.66%. The firm's revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.27) EPS.
View Silk Road Medical's earnings history.

Silk Road Medical's stock was trading at $37.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SILK shares have increased by 38.1% and is now trading at $51.30.
View which stocks have been most impacted by COVID-19.

Silk Road Medical issued an update on its FY 2021 After-Hours earnings guidance on Monday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $102-108 million, compared to the consensus revenue estimate of $111.52 million.

4 brokerages have issued 1-year price objectives for Silk Road Medical's stock. Their forecasts range from $55.00 to $75.00. On average, they anticipate Silk Road Medical's share price to reach $61.75 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price.
View analysts' price targets for Silk Road Medical or view top-rated stocks among Wall Street analysts.

Some companies that are related to Silk Road Medical include Globus Medical (GMED), Inspire Medical Systems (INSP), Haemonetics (HAE), Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Inari Medical (NARI), Nevro (NVRO), ShockWave Medical (SWAV), ICU Medical (ICUI), Glaukos (GKOS), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), AtriCure (ATRC) and iRhythm Technologies (IRTC).
View all of SILK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), The Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), Honeywell International (HON), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical's stock is owned by many different institutional and retail investors. Top institutional investors include AdvisorNet Financial Inc (0.00%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg and Richard Ruedy.
View institutional ownership trends for Silk Road Medical.

SILK stock was bought by a variety of institutional investors in the last quarter, including AdvisorNet Financial Inc.
View insider buying and selling activity for Silk Road Medical or or view top insider-buying stocks.

Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SILK stock can currently be purchased for approximately $51.30.

Silk Road Medical has a market capitalization of $1.76 billion and generates $63.35 million in revenue each year. The company earns $-52,420,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

Silk Road Medical employs 281 workers across the globe.

The official website for Silk Road Medical is www.silkroadmed.com.

Silk Road Medical is headquartered at 1213 INNSBRUCK DR., SUNNYVALE CA, 94089.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]